Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)

Participants: ≥18 years old with Open-angle glaucoma (OAG) or ocular hypertension (OHT)

-open angle inferiorly
-baseline IOP 22-32mmHg

• n=594 patients

Intervention:

Group 1: Bimatoprost implant 10 μg
Group 2: Bimatoprost implant 15 μg
Group 3: Timolol bd

Bimatoprost implant administration was repeated twice at 16-week intervals.

Both dose strengths (10- and 15-μg) of bimatoprost implant were noninferior to timolol in IOP lowering after each administration.

The incidence of corneal and inflammatory treatment-emergent adverse events of interest (e.g., corneal endothelial cell loss, iritis) was higher with bimatoprost implant than timolol, and highest with the 15-μg dose strength.